Cargando…
Tozinameran vaccination in Canada: no change in benefit-risk profile
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907318/ http://dx.doi.org/10.1007/s40278-021-91452-9 |
Ejemplares similares
-
Product monographs for COVID-19 vaccines updated in Canada
Publicado: (2021) -
Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
Publicado: (2021) -
English-only labels for Janssen's COVID-19 vaccine in Canada
Publicado: (2021) -
Health Canada: blood clots with AstraZeneca's COVID-19 vaccine
Publicado: (2021) -
AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada
Publicado: (2021)